WO2009103721A1 - A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof - Google Patents
A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof Download PDFInfo
- Publication number
- WO2009103721A1 WO2009103721A1 PCT/EP2009/051892 EP2009051892W WO2009103721A1 WO 2009103721 A1 WO2009103721 A1 WO 2009103721A1 EP 2009051892 W EP2009051892 W EP 2009051892W WO 2009103721 A1 WO2009103721 A1 WO 2009103721A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- eye
- sawn
- transducers
- cone element
- high intensity
- Prior art date
Links
- 238000002604 ultrasonography Methods 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 42
- 230000008397 ocular pathology Effects 0.000 title claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 47
- 210000004240 ciliary body Anatomy 0.000 claims description 31
- 238000011269 treatment regimen Methods 0.000 claims description 7
- 229920002529 medical grade silicone Polymers 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 description 114
- 208000010412 Glaucoma Diseases 0.000 description 32
- 238000001356 surgical procedure Methods 0.000 description 26
- 210000000695 crystalline len Anatomy 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000012530 fluid Substances 0.000 description 12
- 210000001742 aqueous humor Anatomy 0.000 description 11
- 230000003902 lesion Effects 0.000 description 10
- 210000001585 trabecular meshwork Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 208000002177 Cataract Diseases 0.000 description 8
- 208000002352 blister Diseases 0.000 description 7
- 210000000795 conjunctiva Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000002159 anterior chamber Anatomy 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 230000004410 intraocular pressure Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000001328 optic nerve Anatomy 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 210000003786 sclera Anatomy 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 239000008177 pharmaceutical agent Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 4
- 230000004509 aqueous humor production Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 206010014801 endophthalmitis Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 210000001747 pupil Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 2
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010012565 Developmental glaucoma Diseases 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- 229960000722 brinzolamide Drugs 0.000 description 2
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 2
- 208000029444 double vision Diseases 0.000 description 2
- 230000004406 elevated intraocular pressure Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 208000011323 eye infectious disease Diseases 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- AQOKCDNYWBIDND-ABRBVVEGSA-N 5-trans-17-phenyl trinor Prostaglandin F2alpha ethyl amide Chemical compound CCNC(=O)CCC\C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-ABRBVVEGSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010018325 Congenital glaucomas Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010051283 Fluid imbalance Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000006336 Juvenile glaucoma Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 229940003677 alphagan Drugs 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229940098085 betagan Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 229940099238 diamox Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000028507 juvenile open angle glaucoma Diseases 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- DNTDOBSIBZKFCP-YDALLXLXSA-N levobunolol hydrochloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OC[C@@H](O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-YDALLXLXSA-N 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000001499 parasympathomimetic effect Effects 0.000 description 1
- 229940005542 parasympathomimetics Drugs 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940113006 travatan Drugs 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- 229940108420 trusopt Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00736—Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments
- A61F9/00745—Instruments for removal of intra-ocular material or intra-ocular injection, e.g. cataract instruments using mechanical vibrations, e.g. ultrasonic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0056—Beam shaping elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0056—Beam shaping elements
- A61N2007/006—Lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0056—Beam shaping elements
- A61N2007/0065—Concave transducers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0078—Ultrasound therapy with multiple treatment transducers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
- A61N2007/027—Localised ultrasound hyperthermia with multiple foci created simultaneously
Definitions
- a method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof is provided.
- the present invention is generally directed to a surgical treatment for ocular pathology, and relates more particularly to a device and method for generating high intensity focused ultrasound onto at least one annular segment of the ciliary body of an eye affected by glaucoma
- glaucoma is a significant public health problem, between 1 to 2% of population being suffering from this pathology, because glaucoma is a major cause of blindness.
- the World health organisation considers glaucoma as the third cause of blindness in the world, responsible of 15% of declared blindness occurrences, with an incidence of 2.4 millions persons per year.
- Glaucoma is an insidious health disease because at the first stage glaucoma is asymptomatic; the patient does not feel any pain or any visual problem. When the first visual troubles appear, lesions are commonly already large and despite irreversible.
- Glaucoma is an optic neuropathy, i.e. a disorder of the optic nerve, which usually occurs in the setting of an elevated intraocular pressure. The pressure within the eye increases and this is associated with changes in the appearance and function of the optic nerve. If the pressure remains high enough for a long enough period of time, total vision loss occurs. High pressure develops in an eye because of an internal fluid imbalance.
- the eye is a hollow structure that contains a clear fluid called "aqueous humor."
- Aqueous humor is formed in the posterior chamber of the eye by the ciliary body.
- the fluid which is made at a fairly constant rate, then passes around the lens, through the pupillary opening in the iris and into the anterior chamber of the eye. Once in the anterior chamber, the fluid drains out of the eye through two different routes.
- the fluid In the “uveoscleral" route, the fluid percolates between muscle fibers of the ciliary body. This route accounts for approximately ten percent of the aqueous outflow in humans.
- the primary pathway for aqueous outflow in humans is through the "canalicular" route that involves the trabecular meshwork and Schlemm's canal.
- the aqueous fluid builds up because it cannot exit fast enough.
- the intraocular pressure (lOP) within the eye increases.
- the increased IOP compresses the axons in the optic nerve and also may compromise the vascular supply to the optic nerve.
- the optic nerve carries vision from the eye to the brain. Some optic nerves seem more susceptible to abnormally elevated IOP than other eyes. The only therapeutic approach currently available in glaucoma is to reduce the intraocular pressure.
- Topical beta-adrenergic receptor antagonists such as timolol, levobunolol (Betagan), and betaxolol which decrease aqueous humor production by the ciliary body ;
- Alpha2-adrenergic agonists such as brimonidine (Alphagan) which work by a dual mechanism, decreasing aqueous production and increasing uveo-scleral outflow ;
- Less-selective sympathomimetics like epinephrine and dipivefhn (Propine) which increase outflow of aqueous humor through trabecular meshwork and possibly through uveoscleral outflow pathway;
- Miotic agents parasympathomimetics
- pilocarpine which work by contraction of the ciliary muscle, tightening the trabecular mesh
- cyclodestruction The most practiced surgery intended to reduce aqueous humor production is the cyclodestruction technique.
- cyclodestruction is performed with a laser, it is called cyclophotocoagulation.
- High Intensity focused Ultrasound can be used to obtain a cyclodestruction.
- Canaloplasty is an advanced, nonpenetrating procedure designed to enhance and restore the eye's natural drainage system to provide sustained reduction of lOP. Canaloplasty utilizes breakthrough micro catheter technology in a simple and minimally invasive procedure. To perform a canaloplasty, a doctor will create a tiny incision to gain access to a canal in the eye. A micro catheter will circumnavigate the canal around the iris, enlarging the main drainage channel and its smaller collector channels through the injection of a sterile, gel-like material. The catheter is then removed and a suture is placed within the canal and tightened. By opening the canal, the pressure inside the eye will be relieved. Laser trabeculoplasty may be used to treat open angle glaucoma. A laser spot is aimed at the trabecular meshwork to stimulate opening of the mesh to allow more outflow of aqueous fluid. Usually, half of the angle is treated at a time.
- ALT Argon laser trabeculoplasty
- SLT Selective laser trabeculoplasty
- Laser peripheral iridotomy may be used in patients susceptible to or affected by angle closure glaucoma.
- laser energy is used to make a small full-thickness opening in the iris. This opening equalizes the pressure between the front and back of the iris, causing the iris to move backward.
- a partial thickness flap is made in the scleral wall of the eye, and a window opening made under the flap to remove a portion of the trabecular meshwork.
- the scleral flap is then sutured loosely back in place. This allows fluid to flow out of the eye through this opening, resulting in lowered intraocular pressure and the formation of a bleb or fluid bubble on the surface of the eye.
- Trabeculectomy is associated with many problems. Fibroblasts that are present in the episclera proliferate and migrate and can scar down the scleral flap. Failure from scarring may occur, particularly in children and young adults. Of eyes that have an initially successful trabeculectomy, eighty percent will fail from scarring within three to five years after surgery. To minimize fibrosis, surgeons now are applying antifibrotic agents such as mitomycin C (MMC) and 5-fluorouracil (5-FU) to the scleral flap at the time of surgery. The use of these agents has increased the success rate of trabeculectomy but also has increased the prevalence of hypotony. Hypotony is a problem that develops when aqueous flows out of the eye too fast.
- MMC mitomycin C
- 5-fluorouracil 5-fluorouracil
- the eye pressure drops too low (usually less than 6.0 mmHg); the structure of the eye collapses and vision decreases.
- Antimetabolites directly applied on the surgical site can be used in order to improve the surgical prognosis, especially in high risk of failure (black patients, juvenile glaucoma).
- Trabeculectomy creates a pathway for aqueous fluid to escape to the surface of the eye. At the same time, it creates a pathway for bacteria that normally live on the surface of the eye and eyelids to get into the eye. If this happens, an internal eye infection can occur called endophthalmitis. Endophthalmitis often leads to permanent and profound visual loss. Endophthalmitis can occur anytime after trabeculectomy. Another factor that contributes to infection is the placement of a bleb. Eyes that have trabeculectomy performed infehorly have about five times the risk of eye infection than eyes that have a superior bleb. Therefore, initial trabeculectomy is performed superiorly under the eyelid, in either the nasal or temporal quadrant.
- trabeculectomy In addition to scarring, hypotony and infection, there are other complications of trabeculectomy.
- the bleb can tear and lead to profound hypotony.
- the bleb can be irritating and can disrupt the normal tear film, leading to blurred vision.
- Patients with blebs generally cannot wear contact lenses. All of the complications from trabeculectomy stem from the fact that fluid is being diverted from inside the eye to the external surface of the eye.
- Non- perforating deep sclerectomy ab externo This technique allows avoiding to open the anterior chamber of the eye and consequently reduces the risk of postoperative complications.
- the major limitation of this technique is that it is a very difficult surgical technique and only a few surgeons are able to perform it successfully.
- trabeculectomy or sclerectomy When trabeculectomy or sclerectomy doesn't successfully lower the eye pressure, the next surgical step often is an aqueous shunt device.
- glaucoma drainage implants There are several different glaucoma drainage implants. These include the original Molteno implant, the Baerveldt tube shunt, or the valved implants, such as the Ahmed glaucoma valve implant or the ExPress Mini Shunt and the later generation pressure ridge Molteno implants. These are indicated for glaucoma patients not responding to maximal medical therapy, with previous failed guarded filtering surgery (trabeculectomy).
- the flow tube is inserted into the anterior chamber of the eye and the plate is implanted underneath the conjunctiva to allow flow of aqueous fluid out of the eye into a chamber called a bleb.
- the prior art includes a number of such aqueous shunt devices, such as U.S. 4,936,825, U.S. 5,127,901 , U.S. 5,180,362, U.S. 5,433,701 , U.S. 4,634,418, US 4,787,885, U.S. 4,946,436, U.S. 20040015140A1 and U.S. 5,360,399.
- aqueous shunt devices Many complications are associated with aqueous shunt devices. A thickened wall of scar tissue that develops around the plastic plate offers some resistance to outflow and in many eyes limits the reduction in eye pressure. In some eyes, hypotony develops because the flow through the tube is not restricted. The surgery involves operating in the posterior orbit and many patients develop an eye muscle imbalance and double vision post-operatively. Moreover, because they are open to the surface of the eye, a pathway is created for bacteria to get into the eye and endophthalmitis can potentially occur.
- Another strategy consists in destroying a significant proportion of a circular intraocular organ, placed behind the iris: the ciliary body. This organ and particularly the double layer epithelium cells are responsible for aqueous humor production. The destruction of a significant proportion of the ciliary body, technique called cyclodestruction, reduces the production of aqueous humor and consequently reduces the Intra Ocular Pressure.
- the most common technique currently used is the cyclophotocoagulation obtained with a laser diode (810nm).
- a laser diode 810nm
- the surgeons point a laser at the white part of the eye (sclera).
- the laser passes through the sclera to the ciliary body.
- the laser damages parts of the ciliary body so that it will produce less aqueous humor, which lowers eye pressure.
- the procedure is performed with local anaesthesia.
- the problem with cyclophotocoagulation is that many shots are necessary all around the eye globe, so that a sufficient part of the ciliary body is destroyed.
- the apparatus comprises laser means (3, 33) for applying laser radiation for cyclophotocoagulation, an ultrasonic head (4, 40) of an ultrasonic bio microscope for monitoring said laser cyclophotocoagulation, and fixing means for holding the laser means and the ultrasonic head.
- the ultrasonic head generates low intensity ultrasounds to obtain high resolution echographic images of the region to be treated.
- the fixing means serves both to stabilize the patient's eye in the course of the treatment and also to keep the liquid in place on the patient's eye.
- the fixing means comprise two cylinders: an outer cylinder 20a, and an inner cylinder 20b.
- the outer cylinder is adapted to be disposed on the eye of the patient.
- the inner cylinder is destined to support the laser means and the ultrasonic means.
- the inner cylinder is adjoined to the outer cylinder and is adapted to rotate relative to the outer cylinder.
- the laser means generate laser radiations punctually for cyclophotocoagulation of a punctual zone of the region to be treated. Then, the ultrasonic head and the laser means are displaced by rotating the inner cylinder in order to treat another punctual zone of the region of interest. These steps are repeated until all the circumference of the eye has been treated.
- This method presents the inconvenient that it is necessary to repeat the operation (i.e. rotate the inner cylinder, acquire an image, verify that the apparatus is still in place, produce a laser shot) many times to treat the whole region to be treated. In other words, the operation have to be repeated many times so that the all the circumference of the eye can be treated.
- this method may induce damages to the visual functions (due to spot size errors, misalignment between the ultrasonic head, the laser means and the fixing means, etc.).
- the region which is treated i.e. the eye
- the need of repeating an operation many times increases the operative time and thus the error risk factor.
- WO 02/38078 teaching a method of treating an eye, including glaucoma, that comprises the steps of identifying an area of an eye, such as Schlemm's canal for example, focusing a device capable of directing HIFU energy on the area, such as transducer of 4 to 33mm range, generating HIFU energy from the device onto the area wherein the energy transfer from the device to the area results in an increase in temperature of the area.
- this method provides a treatment to glaucoma in a non invasive manner, it presents the inconvenient that it is necessary to repeat the operation many times to treat the eye circumferentially.
- tissues at the neighbourhood of the treatment area can be destroyed leading to blurred vision, eye muscle imbalance or double vision. It is therefore necessary to use an imaging system like a scan ultrasonography or a Magnetic
- Resonance Imaging system said MRI to identify the area to be treated with the greatest precision and to measure changes in the subject eye after each operation.
- a method of treating an ocular pathology by generating high intensity focused ultrasound onto at least two eye's areas comprises at least the following steps of positioning onto the eye a device capable of directing high intensity focused ultrasound onto at least two annular segments, and generating high intensity focused ultrasound energy onto said segments to destroy at least two annular segment of the ciliary body in the eye.
- the high intensity focused ultrasound energy is generated onto at least two annular segments corresponding to at least two segments of the ciliary body of the eye to destroy them.
- the frequency of high intensity focused ultrasound is in a range of about 1 to 20 MHz and more preferably in a range of about 5 to 10 MHz.
- each annular transducer is in an ultrasound burst having duration less than 60 seconds and more preferably less than 20 seconds.
- each annular segment presents an angle comprised between 5 and 160°, and preferably an angle of 44°.
- a device for treatment of an ocular pathology comprises at least one eye ring wherein the proximal end of said eye ring is suitable to be applied onto the globe and means to generate ultrasound beam fixed on the distal end of the eye ring.
- Said means fixed on the distal end of the eye ring are suitable to generate high intensity focused ultrasound beam.
- said means fixed on the distal end of the eye ring are suitable to generate scattered ultrasound beam.
- the eye ring consists in a sawn-off cone element open at both ends wherein the small base is the proximal end and the large base is the distal end.
- the proximal end of the sawn-off cone element comprises an external annular flange suitable to be applied onto the eye globe.
- the proximal edge of the sawn-off cone element comprises an annular groove communicating with at least one hose formed in the sawn-off cone element and connected to a suction device.
- the internal diameter of the proximal end of the sawn-off cone element is sensibly equal to the corneal diameter plus 2 to 6 mm, and more preferably equal to the sum of the corneal diameter with a value of 4 millimetres..
- the internal diameter of the proximal end of the sawn-off cone element can be comprised between 12 and 18 mm and the internal diameter of the distal end of the sawn-off cone element can be comprised between 26 and 34 mm.
- the height of the sawn-off cone element is comprised between 8 and 12 mm.
- the sawn-off cone element is in medical grade silicon or in medical grade polymer.
- Said means to generate high intensity focused ultrasound energy consists in at least two transducers and more preferably 6 transducers, fixed on the distal end of the sawn-off cone element in such a way that said transducers extend toward the revolution axis of said sawn-off cone element.
- Said transducers can be made either in piezocomposite material or in piezoceramic material or in other materials which complies with the production of High Intensity Ultrasound.
- Said transducers can be focused by themselves and have a toric geometry, or a cylindrical geometry or a spherical geometry, or an elliptical geometry or they can be flat and be used in combination with a focusing system like acoustic lens or acoustic reflectors, with a variety of shapes and materials, extending under or in front of said flat annular transducers.
- Acoustic reflectors are well known in therapeutic ultrasound and are currently routinely used in external Shockwave lithotripsy (Focusing water shock waves for lithotripsy by various ellipsoid reflectors -
- said means to generate high intensity dynamically focused ultrasound energy consists in at least two flat transducers having a cylindrical segment shape, fixed on the distal end of the sawn- off cone element in such a way that said transducers extend toward the revolution axis of said sawn-off cone element.
- said means to generate scattered ultrasound beam are means to generate high intensity non focused ultrasound energy consisting in at least two transducers having an annular flat segment shape, fixed on the distal end of the sawn-off cone element in such a way that said transducers extend toward the revolution axis of said sawn-off cone element.
- transducers are connected to a control unit.
- Said device comprises two pairs of three transducers separated by two inactive sectors.
- Transducers are successively activated by the control unit or simultaneously activated by said control unit.
- the means to generate ultrasound beam fixed on the distal end of the eye ring comprise a plurality of transducers arranged according to a treatment pattern. This allows treating the eye circumferentially in one time. Indeed, unlike the methods and apparatuses described for instance in US 4,484,569 and in DE 44 30 720, the apparatus according to the invention allows treating the eye without the need to repeat an operation many times. With regard to US 4 484 569 and DE 44 30 720, the invention allows in particular:
- the device of the present invention do not need to be displaced many times to treat different punctual zones of the region to be treated, - generating extended lesions covering large regions of the ciliary body unlike the apparatus of the prior art which generates only punctual lesions and needs many elementary lesions to be effective,
- the treatment pattern corresponds to the form defined by the regions to be treated.
- the treatment pattern may be annular or semi- annular. In other cases, the treatment pattern may be elliptical, or hexagonal or octagonal.
- the means to generate ultrasound beam comprise a housing, the transducers being placed peripherally over the housing according to the treatment pattern. More preferably, the transducers may be placed peripherally over the whole or a part of the housing. For instance, in one embodiment, the transducers are circumferentially placed over the whole or a part of the circumference of the housing 8.
- FIG. 1 is a schematic perspective view of the device for treatment of an ocular pathology by applying high intensity focused ultrasound according to the invention
- Figure 2 is an elevation view of the device according to the invention positioned to an eye to be treated
- Figure 3 is a partial view in elevation of the eye ring of the device according to the invention.
- Figure 4 is a schematic perspective view of the transducers held by the eye ring of the device according to the invention
- Figure 5 is a top view of the device correctly positioned to the eye to be treated
- Figure 6 is an elevation view of the device correctly positioned to the eye to be treated shown in figure 5,
- Figure 7 is an elevation view of the device during the generation of HIFU energy
- FIG. 8 is a 3D representation of the injured areas by HIFU energy according to the invention.
- Figure 9 is an elevation view of another embodiment of the device according to the invention positioned to an eye to be treated
- Figure 10 is an elevation view of a last embodiment of device according to the invention particularly adapted for increasing the rate of transport of drug through eye tissue.
- the device according to the invention comprises an eye ring 1 wherein the proximal end of said eye ring is suitable to be applied onto the globe of the eye to be treated and (see figure 2) means 2 to generate high intensity focused ultrasound energy, said means being fixed on the distal end of the eye ring.
- Said means are connected to a control unit 3 including a burst generator and means specifying the parameters of the burst such as the frequency, the power and the duration of each burst, the number of bursts (i.e. the number of transducers to be activated) , etc....
- the burst generator comprises at least a sine-wave signal generator at a determined frequency comprised between 5 and 15 MHz, and preferably between 7 and 10 MHz, an amplifier and a Power meter.
- the eye ring 1 consists in a sawn-off cone element opened at both ends wherein the small base is the proximal end and the large base is the distal end.
- the proximal end of the sawn-off cone element 1 comprises an external annular flange 4 suitable to be applied onto the external surface of the eyeglobe, at approximately 2mm of the limbus, the limbus being the junction between the cornea and sclera of the eyeglobe.
- the proximal face of the annular flange 4 presents a concave profile, the radius of curvature of the concave profile being substantially equal to the radius of curvature of the eyeglobe.
- the proximal edge of the sawn-off cone element 1 comprises an annular groove 5 connected to a suction device 6 (figure 1 ) by at least one hose 7 passing through the sawn-off cone element 1 and emerging into the annular groove, said suction device 6 being advantageously controlled by the control unit 3.
- suction device 6 can be independent without departing from the scope of the invention.
- the sawn-off cone element 1 When the sawn-off cone element 1 is applied onto the eye and the suction device 6 is operated, the depression into the annular groove 5 provide a deformation of the conjunctiva of the eye, said deformation forming an o-ring in the annular groove 5.
- the sawn-off cone element 1 is then closely interlinked in such a manner that said sawn-off cone element 1 will follow the micro movements of the eye during the whole treatment time taking less than 2 minutes, and maintaining the quality of the centred position of the device on the visual axis.
- the sawn-off cone element 1 is advantageously obtained in medical grade silicon which is a soft material compatible with the conjunctiva contact. It is obvious that the sawn-off cone element 1 can be obtained in any suitable material for medical purposes well known by the skilled person, and which has been verified as biocompatible, such as biocompatible PVC, without departing with the scope of the invention.
- means 2 to generate high intensity focused ultrasound beam consist in a standing crown 8 holding a plurality of transducers 9 wherein the external radius of said standing crown 8 is sensibly equal to the internal diameter of the distal end of the sawn-off cone element 1.
- the external edge of the standing crown 8 of transducers 9 comprises an annular groove 10 cooperating with an annular lug 11 extending in the sawn-off cone element 1 at the vicinity of it's distal end in such a way that the standing crown 8 is retained at the distal end of the sawn- off cone element 1. In this way, the standing crown 8 extends toward the revolution axis of said sawn-off cone element 1.
- Said transducers 9 are held in the proximal edge of the standing crown 8.
- each transducer 9 is a segment having a concave profile, wherein the concavity is tuned towards the eyeglobe, and more particularly towards the ciliary body as shown in figure 2.
- the proximal edge of the standing crown 8 comprises an annular groove 12 in which extends the connecting cables of the transducers 9, not shown in figure 2..
- the standing crown 8 of transducers 9 comprises two pairs of three transducers 9 separated by two inactive sectors 13.
- Each transducer 9 is a cylindrical segment able to treat 44° of the circumference of the ciliary body, with an internal diameter of 12.8mm and an external diameter of 28mm.
- the standing crown 8 can comprise two or more transducers 9 distributed among the circumference in any manner without departing with the scope of the invention.
- the transducers 9 are successively activated by the control unit 3 to destroy the ciliary body over the whole or a part of its circumference, each transducer 9 providing an internal injury in a shape compatible with the shape of the ciliary bodies of an arc of circle (i.e. lesions in the form of straight lines within an octagon).
- the internal diameter of the proximal end of the sawn-off cone element 1 is sensibly equal to the corneal diameter plus 2 to 6 mm
- the internal diameter of the proximal end of the sawn-off cone element 1 is comprised between 12 and 18 mm and the internal diameter of the distal end of the sawn-off cone element is comprised between 26 and 34 mm. Moreover, the height of the sawn-off cone element 1 is comprised between 8 and 12 mm.
- the surgeon must manipulate the sawn-off cone element 1 as far as the iris ring and the periphery of the cornea are centred in the distal opening of the sawn-off cone element 1 as illustrated in figure 5. If the white ring corresponding to the visible part of the sclera trough the opening of the proximal end of the ring, has a constant thickness, the centring is correct. When the sawn-off cone element 1 is centred on the pupil, the revolution axis of said sawn-off cone element 1 and the optical axis of the eye are merging, referring to figure 6.
- the planes in which extend the distal edge and the proximal edge of the sawn-off cone element 1 are perfectly parallel to the planes of the eye such as iris plane, pupil plane or plane of the ciliary body, and the proximal edge of the sawn-off cone element 1 is at the plumb of the ciliary body.
- the device can comprise two aiming wires 14 extending crosswise and diametrally from the internal edge of the standing crown 8 or another centring system like a circular pad supposed to be centred on the pupil. This allows facilitating the centring of the sawn-off cone element with regard to the eye. To centre the sawn- off cone element 1 , it is necessary to centre the intersection of the aiming wires 14 with the centre of the pupil.
- the device according to the invention can comprise other centring system known from the man skilled in the art for facilitating the centring of the sawn of cone.
- the suction device 6 When the sawn-off cone element 1 is correctly centred onto the eye, the suction device 6 is activated to interlink said sawn-off cone element 1 with the eye.
- the depression into the annular groove 5 provides a deformation of the conjunctiva of the eye, said deformation forming an o-ring in the annular groove 5. This insures a proper maintain in position of the device during all the treatment.
- the sawn-off cone element 1 is then filled with a physiological saline degassed solution, referring to figure 7, the o-ring formed by the deformation of the conjunctiva of the eye in the annular groove ensuring the sealing.
- the physiological saline solution provides a cooling of the eye and the device during the generation of HIFU and an ultrasound coupling media that permits the propagation of ultrasound from transducers 9 to area of interest, i.e. the ciliary body.
- the physiological saline solution moisturizes the cornea of the eye during the treatment.
- physiological saline degassed solution could be substituted by any ultrasound coupling agent such as aqueous media or lipophilic media without departing of the scope of the invention.
- each transducer is elongated so that each transducer provides an internal injury in the shape of straight lines or arc of circle as represented in figure 8.
- the X-Y plane represents the free end of the eyeglobe and that the height represents the depth of the eye globe.
- the use of elongated transducers allows producing unpunctual lesions more extended than the punctual lesions obtained with the apparatuses described in US 4 484 569 and DE 44 30 720. This improves the efficiency of the treatment since it remains less non- destroyed tissues (with regard to results obtained with the apparatuses described in US 4 484 569 and DE 44 30 720).
- the treatment according to the invention is advantageously an ambulatory treatment whose duration is about 2 minutes for the patient.
- the device comprises in the same manner as preceding a sawn-off cone element 1 opened at both ends wherein the small base is the proximal end and the large base is the distal end and means 2 to generate high intensity focused ultrasound beam, said means being fixed on the distal end of the sawn-off cone element 1.
- Said means 2 consist in a standing crown 8 holding a plurality of transducers 9 wherein the external radius of said standing crown 8 is sensibly equal to the internal diameter of the distal end of the sawn-off cone element 1.
- the external edge of the standing crown 8 of transducers 9 comprises an annular groove 10 cooperating with an annular lug 11 extending in the sawn-off cone element 1 at the vicinity of it's distal end in such a way that the standing crown 8 is retained at the distal end of the sawn-off cone element 1. In this way, the standing crown 8 extends toward the revolution axis of said sawn-off cone element 1.
- each transducer 9 is held in the proximal edge of the standing crown 8. Moreover, each transducer 9 is a flat segment having a globally rectangular profile that extends sensibly parallel to the proximal and distal edge of the sawn-off cone element 1.
- the device comprises a focusing acoustic lens 15 extending under said transducers 9, i.e. held by the standing crown 8 and extending between the proximal edge of the standing crown 8 and the proximal edge of the sawn-off cone element 1.
- Said focusing acoustic lens presents a cylindrical shape and a concave edge wherein the concavity is tuned towards the eyeglobe, and more particularly towards the ciliary body as shown in figure 9, to focalize HIFU onto the area of interest, i.e. the ciliary body of the eye.
- the standing crown 8 comprises an annular channel 16 in which extends the connecting cables of the transducers 9, not shown in figure 9.
- the standing crown 8 of transducers 9 comprises two pairs of three transducers 9 separated by two inactive sectors 13.
- Each transducer 9 is an annular segment of 44° with an internal diameter of 12.8mm and an external diameter of 24.3mm. It is obvious that means to generate high intensity focused ultrasound energy can consist in at least two transducers having a cylindrical segment shape, fixed on the distal end of the sawn-off cone element in such a way that said transducers extend toward the revolution axis of said sawn-off cone element.
- said means to generate high intensity focused ultrasound energy can be substituted by means to generate high intensity dynamically focused ultrasound energy consisting in at least two annular array transducers having a toric segment shape, fixed on the distal end of the sawn-off cone element in such a way that said annular array transducers extend toward the revolution axis of said sawn-off cone element.
- the device according to the invention can be used for treatment of open angle glaucoma, but with a different approach than cyclodestruction. Indeed as described in WO 2008/024795, ultrasound can be used for their vibrating properties on small particles.
- the device according to the invention can easily produce a vibration obtained with the propagation of an ultrasonic beam, transmitted to the trabecular meshwork, which unlike the apparatus described in WO 2008/024795 can concern the whole circumference of the trabeculum at the same time, more rapidly and in only one step. Moreover, with the device according to the invention, thanks to the ring which allows centering and fixation on the eye globe, this technique can be substantially improved compared to the device described in WO 2008/024795. In the case where the device according to the invention is used to produce vibration, the power is lower and the duration of the energy generated by each transducer is shorter than previously explained, and is repeated periodically with many burst successively.
- the duration of the energy generated by each annular transducer is less than 10 seconds, and more preferably less than 5 seconds, the application of is repeated 2 times or more. Indeed, in such case, the aim is no longer to produce lesions (i.e. destroy the target region as explained with reference to the ciliary bodies) but to produce vibration. So it is necessary to limit the duration of the energy generated in order to ensure that the target region (i.e. the trabeculum in the present case) is not burned.
- Another embodiment of the device according to the invention used as a treatment of open angle glaucoma with the vibration technique applied on the trabecular meshwork, can be combined with a phacoemulsification machine.
- the particles like cell debris, fibrin, pigment or other responsible for the loss of drainage efficiency of trabeculum, are delivered from their adherence to the trabecular meshwork, and are circulating in the aqueous humor it is obvious that they will rapidly be cached again by trabeculum, reducing consequently the efficiency of the treatment by the vibration technique.
- the idea for this preferred embodiment is to combine this treatment with a phacoemulsification machine, and preferably during a cataract surgery, because during this surgery the anterior chamber and the liquid it contains, are completely washed with a balanced salt solution circulating in the irrigation / aspiration circuit, so that if the vibration technique is performed before the cataract surgery, all the debris delivered from their adherence on the trabecular meshwork, will be washed out of the anterior chamber, increasing the efficiency of the treatment. It is well known that cataract surgery is more frequent in older population. It is well known too that glaucoma is more frequent in the same population. For this reason, combined surgeries, including cataract and trabeculectomy are more and more frequent.
- the idea for this preferred embodiment is to add a new feature to the phacoemulsification machines, already often equipped with vitrectomy features, which will be the glaucoma prevention by a systematic cleaning of the trabeculum with the ultrasound vibration technique, when a cataract surgery is performed in a patient with a too high intra ocular pressure (>15 - 18mm Hg). It is obvious that the device according to the invention could be adapted for other ocular pathology such as for a cataract surgery by focusing the HIFU onto the crystalline lens rather than onto the ciliary body.
- the goal of the cataract surgery is to replace the natural crystalline lens by an artificial lens, when the natural crystalline lens has lost its transparency.
- a first step it is necessary to remove the natural lens surgically.
- this extraction is performed by a phacoemulsification procedure.
- the surgeon uses a machine equipped with an ultrasonic hand piece.
- the tip of the hand piece sculpts the crystalline lens and simultaneously irrigates and sucks the lens debris.
- the device could be used advantageously before the surgery to modify the consistence of the crystalline lens and to reduce the adherence between the cortex and the capsular bag. This could be done in order to: reduce the dimension of the corneal incision, reduce the duration of the surgery and increase the quality of the extraction by reducing the quantity of residual cortex, which is responsible for postoperative capsular bag opacification.
- the device comprises in the same manner as preceding a sawn-off cone element 1 opened at both ends wherein the small base is the proximal end and the large base is the distal end and means 9 to generate scattered ultrasound beam, said means being fixed on the distal end of the sawn-off cone element 1.
- Such technique as described in WO 2007/081750 could be particularly useful to avoid intra vitreal injection of pharmaceutical agents, for treating chronic or acute eye diseases.
- the cited invention doesn't describe a device adapted to the eye globe intended to facilitate the manipulation, and with a large area surface covered by high intensity ultrasound.
- the present embodiment of the invention as described above could facilitate the manipulation with the use of a centring and fixation ring, and increase the efficacy of the treatment thanks to a larger area covered by the ultrasound beam.
- Said means 17 consist in a standing crown 8 holding a plurality of transducers 9 wherein the external radius of said standing crown 8 is sensibly equal to the internal diameter of the distal end of the sawn-off cone element 1.
- the external edge of the standing crown 8 of transducers 9 comprises an annular groove 10 cooperating with an annular lug 11 extending in the sawn-off cone element 1 at the vicinity of it's distal end in such a way that the standing crown 8 is retained at the distal end of the sawn- off cone element 1. In this way, the standing crown 8 extends toward the revolution axis of said sawn-off cone element 1.
- Said transducers 9 are held in the proximal edge of the standing crown 8.
- each transducer 9 is an annular segment suitable to generate scattered ultrasound beam into the sawn-off cone element 1 , said sawn-off cone element 1 being filed with a coupling media 18 such as physiological saline degassed solution containing a pharmaceutical formulation and/or micro carriers.
- a coupling media 18 such as physiological saline degassed solution containing a pharmaceutical formulation and/or micro carriers.
- said transducers 9 has a globally rectangular profile that are inclined globally toward the centre of the proximal edge of the sawn-off cone element 1.
- means to generate scattered ultrasound beam can be means to generate high intensity non focused ultrasound energy consisting in at least two transducers having an annular or rectangular flat segment shape, fixed on the distal end of the sawn-off cone element in such a way that said transducers extend toward the revolution axis of said sawn-off cone element 1.
- Said transducers 9 are circumferentially placed over the whole or a part of the circumference of the standing crown 8.
- the suction device 6 is activated to interlink said sawn-off cone element 1 with the eye.
- the depression into the annular groove 5 provides a deformation of the conjunctiva of the eye, said deformation forming an o-ring in the annular groove 5.
- the sawn-off cone element 1 is then filled with a physiological saline degassed solution containing the appropriate pharmaceutical agents, the o-ring formed by the deformation of the conjunctiva of the eye in the annular groove ensuring the sealing.
- the frequency and/or the power and/or the duration of pulses are selected or already predetermined and the transducers 9 are successively or simultaneously activated by the control unit to increase the porosity of the cornea and of the sclera of the eye and to homogenise the pharmaceutical agent in the coupling media, by mixing it, that enhance the transport rate of the pharmaceutical agents across the cornea an scleral tissues reaching the anterior and posterior segments of the eye and avoiding intra ocular injections.
- the device according to the invention could be used in case of any medical treatment of eye diseases with local drug administration.
- this kind of treatment is administered topically with eye drops.
- eye drops must be administered many times per day, which is a constraint and often leads to the patient's demotivation, even if new drugs formulations have recently reduced in some cases to once a day the number of eyedrops administrations.
- Other kinds of treatments require intra-vitreal injections of the drugs directly in the eye.
- the device according to the invention could be used for example to avoid intra- vitreal injections of antibiotics, anti viral drugs, anti inflammatory drugs, chemotherapy agents or new molecules like anti-angiogenics for the treatment of diabetic macular edema or of age related macular degeneration.
- the intra-vitreal injections are of potential high risk.
- the geometric shape of our device could allow its filling with a liquid containing active drug.
- a particular model of the device designed to produce a non focused ultrasound beam, with a low power which doesn't generate lesions in the tissues could allow the penetration of active drugs in the intraocular structures.
- the standing crown 8 holding means 9 to generate scattered ultrasound beam is advantageously removable and can be substituted by a standing crown 8 holding means 2 to generate HIFU beam as disclosed in figure 2 and 9.
- This written description uses examples to disclose the invention, including the best mode, and also to enable any person skilled in the art to make and use the invention.
- the scope of the subject matter described herein is defined by the claims, and may include other examples that occur to those skilled in the art. Such other examples are intended to be within the scope of the claims if they have structural elements that do not differ from the literal language of the claims, or if they include equivalent structural elements with insubstantial differences from the literal languages of the claims.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Ophthalmology & Optometry (AREA)
- Radiology & Medical Imaging (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Surgical Instruments (AREA)
- Prostheses (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
Abstract
Description
Claims
Priority Applications (28)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09712991T ES2426120T3 (en) | 2008-02-19 | 2009-02-18 | Device to treat an ocular pathology by applying a high intensity focused ultrasound |
BRPI0908386A BRPI0908386B8 (en) | 2008-02-19 | 2009-02-18 | device for the treatment of an eye pathology by applying high-intensity focal ultrasound |
US12/867,977 US9403039B2 (en) | 2008-02-19 | 2009-02-18 | High intensity focused ultrasound device and method for ocular pathology treatment |
AU2009216751A AU2009216751B2 (en) | 2008-02-19 | 2009-02-18 | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof |
MX2010009027A MX2010009027A (en) | 2008-02-19 | 2009-02-18 | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof. |
DK09712991.0T DK2257251T3 (en) | 2008-02-19 | 2009-02-18 | DEVICE FOR TREATMENT OF AN EYE DISEASE USING HIGH-INTENSIVE FOCUSED ULTRA SOUND |
CA2714116A CA2714116C (en) | 2008-02-19 | 2009-02-18 | A device for treating an ocular pathology by applying high intensity focused ultrasound |
JP2010547165A JP2011512213A (en) | 2008-02-19 | 2009-02-18 | Method of treating ocular lesions by applying high-intensity focused ultrasound and its apparatus |
CN200980105350.1A CN101969899B (en) | 2008-02-19 | 2009-02-18 | Method of treating ocular pathology by applying high intensity focused ultrasound and device thereof |
EP09712991.0A EP2257251B1 (en) | 2008-02-19 | 2009-02-18 | A device for treating an ocular pathology by applying high intensity focused ultrasound |
RU2010138619/14A RU2501539C2 (en) | 2008-02-19 | 2009-02-18 | Method of treating ocular pathology using high-intensity focused ultrasound and apparatus for implementing it |
CA2751906A CA2751906C (en) | 2009-02-18 | 2009-08-18 | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature |
BRPI0924350A BRPI0924350B8 (en) | 2008-02-19 | 2009-08-18 | ultrasound device comprising means for generating an ultrasound beam having a concave segment shape having a unique curvature |
KR1020117020828A KR101638140B1 (en) | 2009-02-18 | 2009-08-18 | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvatrue |
JP2011550430A JP5490826B2 (en) | 2008-02-19 | 2009-08-18 | Ultrasonic apparatus provided with ultrasonic beam generating means exhibiting the shape of a concave portion having a single curvature |
RU2011138181/14A RU2515509C2 (en) | 2009-02-18 | 2009-08-18 | Ultrasonic device comprising ultrasonic beam generators shaped as concave segments with one curvature |
AU2009340220A AU2009340220B2 (en) | 2009-02-18 | 2009-08-18 | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature |
US13/202,079 US9517359B2 (en) | 2009-02-18 | 2009-08-18 | High intensity focused ultrasound device with a concave segment shaped transducer for eye treatment |
PCT/EP2009/060678 WO2010094349A1 (en) | 2009-02-18 | 2009-08-18 | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature |
CN200980156978.4A CN102316834B (en) | 2008-02-19 | 2009-08-18 | Ultrasound apparatus comprising means for generating a concave segmental shaped ultrasound beam having a single curvature |
EP09781958.5A EP2398432B1 (en) | 2009-02-18 | 2009-08-18 | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature |
MX2011008705A MX342224B (en) | 2009-02-18 | 2009-08-18 | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature. |
US13/202,084 US9259597B2 (en) | 2008-02-19 | 2009-08-26 | Method of treating an ocular pathology by applying ultrasound to the trabecular meshwork and device thereof |
PCT/EP2009/061014 WO2010094353A1 (en) | 2009-02-18 | 2009-08-26 | A method of treating an ocular pathology by applying ultrasound to the trabecular meshwork and device thereof |
CA2751908A CA2751908A1 (en) | 2009-02-18 | 2009-08-26 | A method of treating an ocular pathology by applying ultrasound to the trabecular meshwork and device thereof |
EP09782230.8A EP2398433B1 (en) | 2009-02-18 | 2009-08-26 | Phacoemulsificator applying ultrasound to an ocular globe |
IL207425A IL207425A (en) | 2008-02-19 | 2010-08-05 | Device for treatment of an ocular pathology |
IL214456A IL214456A0 (en) | 2009-02-18 | 2011-08-04 | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08101765A EP2092916A1 (en) | 2008-02-19 | 2008-02-19 | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof |
EP08101765.9 | 2008-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009103721A1 true WO2009103721A1 (en) | 2009-08-27 |
Family
ID=40110965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/051892 WO2009103721A1 (en) | 2008-02-19 | 2009-02-18 | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof |
Country Status (13)
Country | Link |
---|---|
US (3) | US9403039B2 (en) |
EP (2) | EP2092916A1 (en) |
JP (3) | JP2011512213A (en) |
KR (1) | KR101601798B1 (en) |
CN (2) | CN101969899B (en) |
BR (2) | BRPI0908386B8 (en) |
CA (1) | CA2714116C (en) |
DK (1) | DK2257251T3 (en) |
ES (1) | ES2426120T3 (en) |
IL (1) | IL207425A (en) |
MX (1) | MX2010009027A (en) |
RU (1) | RU2501539C2 (en) |
WO (1) | WO2009103721A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012136752A1 (en) | 2011-04-05 | 2012-10-11 | Eye Tech Care | Device for ocular ultrasound therapy having a reflector |
EP2601917A1 (en) | 2011-12-08 | 2013-06-12 | Eye Tech Care | System and method for determining the optimal size of a device for generating ultrasound |
US8652073B2 (en) | 2009-08-18 | 2014-02-18 | Eye Tech Care | Parameters for an ultrasound device comprising means to generate high intensity ultrasound beam |
WO2016177910A1 (en) | 2015-05-07 | 2016-11-10 | Eye Tech Care | Method for adjusting operating parameters for the power supply of a transducer |
WO2017053673A1 (en) * | 2015-09-24 | 2017-03-30 | Visionage Therapies, Llc | Sonic and ultrasonic methods and apparatus for treatment of glaucoma |
FR3062057A1 (en) * | 2017-01-20 | 2018-07-27 | Eye Tech Care | OCULAR PROBE WITH MEANS FOR GENERATING ULTRASONIC DISPLACABLES |
FR3104409A1 (en) | 2019-12-16 | 2021-06-18 | Eye Tech Care | TREATMENT DEVICE INCLUDING A COUPLING FLUID DETECTOR |
FR3104410A1 (en) | 2019-12-16 | 2021-06-18 | Eye Tech Care | PROCESSING DEVICE INCLUDING A TOOL HOLDER AND A TOOL HAVING MEANS OF MOVEMENT IN CONTACT ROTATION |
FR3104408A1 (en) | 2019-12-16 | 2021-06-18 | Eye Tech Care | PROCESSING DEVICE INCLUDING A TOOL HOLDER AND A TOOL INCLUDING MEANS OF MOVEMENT IN CONTACTLESS ROTATION |
US11097131B2 (en) | 2015-03-31 | 2021-08-24 | Eye Tech Care | Eye probe for treatment with ultrasonic waves |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE472335T1 (en) | 2001-05-31 | 2010-07-15 | Novartis Vaccines & Diagnostic | CHIMERE ALPHAVIRUS REPLICON PARTICLES |
US20220096112A1 (en) | 2007-01-02 | 2022-03-31 | Aquabeam, Llc | Tissue resection with pressure sensing |
US8814921B2 (en) | 2008-03-06 | 2014-08-26 | Aquabeam Llc | Tissue ablation and cautery with optical energy carried in fluid stream |
US9232959B2 (en) | 2007-01-02 | 2016-01-12 | Aquabeam, Llc | Multi fluid tissue resection methods and devices |
EP2092916A1 (en) | 2008-02-19 | 2009-08-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof |
WO2009155114A2 (en) * | 2008-05-30 | 2009-12-23 | The Regents Of The University Of Colorado, A Body Corporate | A non-invasive device for lowering intraocular pressure |
US9999710B2 (en) | 2009-01-07 | 2018-06-19 | Med-Logics, Inc. | Tissue removal devices, systems and methods |
WO2010085660A2 (en) | 2009-01-23 | 2010-07-29 | Roger Williams Hospital | Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
WO2011137449A2 (en) | 2010-04-30 | 2011-11-03 | Seros Medical, Llc | Method and apparatus for treatment of ocular tissue using combined modalities |
WO2011138783A1 (en) * | 2010-05-05 | 2011-11-10 | Technion Research & Development Foundation Ltd. | Method and system of manipulating bilayer membranes |
US9566456B2 (en) | 2010-10-18 | 2017-02-14 | CardioSonic Ltd. | Ultrasound transceiver and cooling thereof |
US20120095371A1 (en) | 2010-10-18 | 2012-04-19 | CardioSonic Ltd. | Ultrasound transducer and cooling thereof |
US20130218068A1 (en) | 2010-10-18 | 2013-08-22 | CardioSonic Ltd. | Therapeutics reservoir |
US9308126B2 (en) | 2010-11-29 | 2016-04-12 | The Regents Of The University Of Colorado, A Body Corporate | Non-invasive devices and methods for lowering intra-ocular pressure |
JP2014523263A (en) * | 2011-05-20 | 2014-09-11 | ドヘニー アイ インスティテュート | Ocular ultrasound probe |
KR101246557B1 (en) * | 2011-06-21 | 2013-03-25 | 주식회사 제이시스메디칼 | Non-invasive skin care equipment Using ultrasonic |
US8911552B2 (en) * | 2011-08-12 | 2014-12-16 | Wafertech, Llc | Use of acoustic waves for purging filters in semiconductor manufacturing equipment |
DE102011116368A1 (en) * | 2011-10-17 | 2013-04-18 | Carl Zeiss Meditec Ag | Apparatus and method for extracapsular surgical cataract treatment |
CN102488609B (en) * | 2011-11-23 | 2013-07-17 | 王铭 | Ultrasonic sinus cavity therapeutic apparatus |
FR2983700B1 (en) * | 2011-12-08 | 2014-03-07 | Eye Tech Care | SUCCIONING DEVICE FOR THE TREATMENT OF AN OCULAR PATHOLOGY |
US9504604B2 (en) | 2011-12-16 | 2016-11-29 | Auris Surgical Robotics, Inc. | Lithotripsy eye treatment |
US9125722B2 (en) * | 2012-02-09 | 2015-09-08 | Donald N. Schwartz | Device for the ultrasonic treatment of glaucoma having a concave tip |
CN104203078B (en) | 2012-02-29 | 2018-04-20 | 普罗赛普特生物机器人公司 | The cutting tissue of automated image guiding and processing |
US10357304B2 (en) | 2012-04-18 | 2019-07-23 | CardioSonic Ltd. | Tissue treatment |
US10383765B2 (en) | 2012-04-24 | 2019-08-20 | Auris Health, Inc. | Apparatus and method for a global coordinate system for use in robotic surgery |
US11357447B2 (en) | 2012-05-31 | 2022-06-14 | Sonivie Ltd. | Method and/or apparatus for measuring renal denervation effectiveness |
AU2014257365B2 (en) | 2012-09-04 | 2019-01-24 | Liquet Technologies, Inc. | Tissue removal devices, systems and methods |
US10231867B2 (en) | 2013-01-18 | 2019-03-19 | Auris Health, Inc. | Method, apparatus and system for a water jet |
US9867635B2 (en) | 2013-03-08 | 2018-01-16 | Auris Surgical Robotics, Inc. | Method, apparatus and system for a water jet |
US10080576B2 (en) | 2013-03-08 | 2018-09-25 | Auris Health, Inc. | Method, apparatus, and a system for facilitating bending of an instrument in a surgical or medical robotic environment |
US10149720B2 (en) | 2013-03-08 | 2018-12-11 | Auris Health, Inc. | Method, apparatus, and a system for facilitating bending of an instrument in a surgical or medical robotic environment |
BR112015021898A2 (en) | 2013-03-15 | 2017-07-18 | Aleyegn Inc | scleral translocation elastomodulation methods and apparatus |
US10933259B2 (en) | 2013-05-23 | 2021-03-02 | CardioSonic Ltd. | Devices and methods for renal denervation and assessment thereof |
WO2014201165A1 (en) | 2013-06-11 | 2014-12-18 | Auris Surgical Robotics, Inc. | System for robotic assisted cataract surgery |
US10426661B2 (en) | 2013-08-13 | 2019-10-01 | Auris Health, Inc. | Method and apparatus for laser assisted cataract surgery |
US20150057583A1 (en) * | 2013-08-24 | 2015-02-26 | Alcon Research, Ltd. | Trabecular meshwork stimulation device |
US9980785B2 (en) | 2013-10-24 | 2018-05-29 | Auris Health, Inc. | Instrument device manipulator with surgical tool de-articulation |
KR102332023B1 (en) | 2013-10-24 | 2021-12-01 | 아우리스 헬스, 인크. | System for Robotic-Assisted Endolumenal Surgery and Related Methods |
WO2015070889A1 (en) * | 2013-11-12 | 2015-05-21 | Sabanci University | Device and method for performing thermal keratoplasty using high intensity focused ultrasounds |
US9788910B2 (en) | 2014-07-01 | 2017-10-17 | Auris Surgical Robotics, Inc. | Instrument-mounted tension sensing mechanism for robotically-driven medical instruments |
US10792464B2 (en) | 2014-07-01 | 2020-10-06 | Auris Health, Inc. | Tool and method for using surgical endoscope with spiral lumens |
JP6938507B2 (en) | 2015-09-09 | 2021-09-22 | オーリス ヘルス インコーポレイテッド | Instrument device manipulator for surgical support robot system |
JP2018529480A (en) * | 2015-10-06 | 2018-10-11 | エルアイジン テクノロジーズ エルエルシー | Ultrasonic orientation cavitation method and system for eye treatment |
EP3380835B1 (en) | 2015-11-26 | 2020-03-18 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Method for determining a mechanical property of a layered soft material |
US10624785B2 (en) | 2016-01-30 | 2020-04-21 | Carl Zeiss Meditec Cataract Technology Inc. | Devices and methods for ocular surgery |
FI3245988T3 (en) | 2016-05-18 | 2024-02-22 | Sonikure Holdings Ltd | System for ultrasound-enhanced transscleral delivery of drugs |
WO2018167099A2 (en) | 2017-03-13 | 2018-09-20 | Kejako Sa | Accommodative lens device |
US20200094080A1 (en) | 2017-03-20 | 2020-03-26 | Sonivie Ltd. | Method for treating heart failure by improving ejection fraction of a patient |
WO2018204699A1 (en) | 2017-05-04 | 2018-11-08 | Iantech, Inc. | Devices and methods for ocular surgery |
WO2019236615A1 (en) | 2018-06-05 | 2019-12-12 | Carl Zeiss Meditec Cataract Technology Inc. | Ophthalmic microsurgical tools, systems, and methods of use |
US10369049B1 (en) * | 2018-08-17 | 2019-08-06 | Iridex Corporation | Probes having fiber taper and fluid collection channel for ophthalmic laser treatment |
RU2688960C1 (en) * | 2018-12-24 | 2019-05-23 | федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Method of combined surgical treatment of secondary glaucoma caused by emulsification of silicone |
EP4279042A3 (en) | 2019-02-01 | 2024-02-07 | Carl Zeiss Meditec Cataract Technology Inc. | Ophthalmic cutting instruments having integrated aspiration pump |
CN111603303A (en) * | 2019-02-25 | 2020-09-01 | 中国科学院声学研究所 | A system for minimally invasive treatment of cataract with focused ultrasound |
US11103382B2 (en) | 2019-04-19 | 2021-08-31 | Elt Sight, Inc. | Systems and methods for preforming an intraocular procedure for treating an eye condition |
US11389239B2 (en) | 2019-04-19 | 2022-07-19 | Elios Vision, Inc. | Enhanced fiber probes for ELT |
US11076933B2 (en) | 2019-04-19 | 2021-08-03 | Elt Sight, Inc. | Authentication systems and methods for an excimer laser system |
US11672475B2 (en) | 2019-04-19 | 2023-06-13 | Elios Vision, Inc. | Combination treatment using ELT |
KR20220010739A (en) | 2019-05-17 | 2022-01-26 | 칼 짜이스 메디텍 캐터랙트 테크놀로지 인크. | Ophthalmic Cutting Instrument with Integral Suction Pump |
EP3979960A2 (en) | 2019-06-07 | 2022-04-13 | Carl Zeiss Meditec Cataract Technology Inc. | Multi-stage trigger for ophthalmology cutting tool |
RU2726462C1 (en) * | 2019-11-26 | 2020-07-14 | федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Method of selecting patients with primary open-angle glaucoma for selective laser trabeculoplasty |
EP4181844A4 (en) * | 2020-07-14 | 2024-07-17 | Tel Hashomer Medical Research, Infrastructure and Services Ltd. | ACOUSTIC EYE DEVICE AND METHOD THEREFOR |
US12127979B2 (en) | 2020-09-16 | 2024-10-29 | Johnson & Johnson Surgical Vision, Inc. | Robotic cataract surgery using focused ultrasound |
CA3224096A1 (en) * | 2021-06-30 | 2023-01-05 | Nir KATCHINSKIY | System, method, and devices for tissue manipulation using electronically steerable ultrasound transducer |
US11877951B1 (en) | 2022-08-30 | 2024-01-23 | Elios Vision, Inc. | Systems and methods for applying excimer laser energy with transverse placement in the eye |
US11918516B1 (en) | 2022-08-30 | 2024-03-05 | Elios Vision, Inc. | Systems and methods for treating patients with closed-angle or narrow-angle glaucoma using an excimer laser unit |
US11903876B1 (en) * | 2022-08-30 | 2024-02-20 | Elios Vision, Inc. | Systems and methods for prophylactic treatment of an eye using an excimer laser unit |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU591186A1 (en) * | 1976-07-23 | 1978-02-05 | Serov Vilenin Nikolaevich | Method of treating eye diseases |
US4484569A (en) * | 1981-03-13 | 1984-11-27 | Riverside Research Institute | Ultrasonic diagnostic and therapeutic transducer assembly and method for using |
DE4430720A1 (en) * | 1993-12-21 | 1995-06-22 | Zeiss Carl Fa | Laser cyclophotocoagulation device for treating glaucoma |
WO2001080708A2 (en) * | 2000-04-21 | 2001-11-01 | Txsonics Ltd. | Systems and methods for reducing secondary hot spots in a phased array focused ultrasound system |
US20020016557A1 (en) * | 1997-02-14 | 2002-02-07 | Duarte Luiz R. | Ultrasonic treatment for wounds |
US20080275370A1 (en) * | 2007-05-01 | 2008-11-06 | Mcintyre Jon T | Apparatus and method for treating visual disorders |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3941122A (en) * | 1974-04-08 | 1976-03-02 | Bolt Beranek And Newman, Inc. | High frequency ultrasonic process and apparatus for selectively dissolving and removing unwanted solid and semi-solid materials and the like |
SU554863A1 (en) * | 1975-08-07 | 1977-04-25 | Московский научно-исследовательский институт глазных болезней им.Гельмгольца | Device for irradiating the eye with ultrasonic vibrations |
FR2443072A1 (en) * | 1978-04-20 | 1980-06-27 | Commissariat Energie Atomique | OPTICAL FOR EXPLORING A PART BY A BEAM |
US4634418A (en) | 1984-04-06 | 1987-01-06 | Binder Perry S | Hydrogel seton |
US4787885A (en) | 1984-04-06 | 1988-11-29 | Binder Perry S | Hydrogel seton |
US4936825A (en) | 1988-04-11 | 1990-06-26 | Ungerleider Bruce A | Method for reducing intraocular pressure caused by glaucoma |
DE3932959C1 (en) * | 1989-10-03 | 1991-04-11 | Richard Wolf Gmbh, 7134 Knittlingen, De | |
DE3932967A1 (en) * | 1989-10-03 | 1991-04-11 | Wolf Gmbh Richard | ULTRASONIC SHOCK WAVE CONVERTER |
SU1724225A1 (en) * | 1989-11-14 | 1992-04-07 | Московский научно-исследовательский институт глазных болезней им.Гельмгольца | Appliance for ultrasonic treatment of the eye and orbit |
US4946436A (en) | 1989-11-17 | 1990-08-07 | Smith Stewart G | Pressure-relieving device and process for implanting |
US5180362A (en) | 1990-04-03 | 1993-01-19 | Worst J G F | Gonio seton |
US5127901A (en) | 1990-05-18 | 1992-07-07 | Odrich Ronald B | Implant with subconjunctival arch |
US5360399A (en) | 1992-01-10 | 1994-11-01 | Robert Stegmann | Method and apparatus for maintaining the normal intraocular pressure |
US5230334A (en) | 1992-01-22 | 1993-07-27 | Summit Technology, Inc. | Method and apparatus for generating localized hyperthermia |
WO1994012131A1 (en) | 1992-11-20 | 1994-06-09 | Shinseiro Okamoto | Cornea operating method and apparatus |
JP3235748B2 (en) * | 1992-11-25 | 2001-12-04 | 東芝セラミックス株式会社 | Manufacturing method of shock wave generator |
JPH06277223A (en) * | 1993-03-24 | 1994-10-04 | Toshiba Corp | Impulse wave medical treatment device |
WO1995015134A1 (en) * | 1993-12-02 | 1995-06-08 | Sunrise Technologies, Inc. | Laser system for reshaping the cornea |
US5591127A (en) * | 1994-01-28 | 1997-01-07 | Barwick, Jr.; Billie J. | Phacoemulsification method and apparatus |
JPH0871078A (en) * | 1994-09-06 | 1996-03-19 | Toshiba Ceramics Co Ltd | Ultrasonic generator |
JPH0871079A (en) * | 1994-09-06 | 1996-03-19 | Toshiba Ceramics Co Ltd | Ultrasonic generator |
US5601548A (en) | 1994-11-07 | 1997-02-11 | Ophthalmic International, L.L.C. | Open angle glaucoma treatment apparatus and method |
US5433701A (en) | 1994-12-21 | 1995-07-18 | Rubinstein; Mark H. | Apparatus for reducing ocular pressure |
SE504146C2 (en) * | 1995-03-16 | 1996-11-18 | Lars Ekberg | ultrasound probe |
US5645530A (en) | 1995-08-28 | 1997-07-08 | Alcon Laboratories, Inc. | Phacoemulsification sleeve |
DE19540439C2 (en) | 1995-10-30 | 1999-04-22 | Schwind Gmbh & Co Kg Herbert | Device for corneal surgery |
US5860994A (en) * | 1996-07-30 | 1999-01-19 | Yaacobi; Yoseph | Remotely operable intraocular surgical instrument for automated capsulectomies |
US6039689A (en) | 1998-03-11 | 2000-03-21 | Riverside Research Institute | Stripe electrode transducer for use with therapeutic ultrasonic radiation treatment |
US6948843B2 (en) * | 1998-10-28 | 2005-09-27 | Covaris, Inc. | Method and apparatus for acoustically controlling liquid solutions in microfluidic devices |
RU2197926C2 (en) | 1999-04-26 | 2003-02-10 | Рязанский государственный медицинский университет им. акад. И.П. Павлова | Method for treating glaucoma cases |
US6267752B1 (en) * | 1999-08-05 | 2001-07-31 | Medibell Medical Vision Technologies, Ltd. | Multi-functional eyelid speculum |
US6679855B2 (en) * | 2000-11-07 | 2004-01-20 | Gerald Horn | Method and apparatus for the correction of presbyopia using high intensity focused ultrasound |
ES2192123B1 (en) | 2001-03-21 | 2005-02-01 | Novosalud, S.L. | SUCTION RING FOR MICROCHERATOMOS. |
US7094225B2 (en) * | 2001-05-03 | 2006-08-22 | Glaukos Corporation | Medical device and methods of use of glaucoma treatment |
DE20221042U1 (en) | 2001-10-24 | 2004-11-18 | Carriazo, Cesar C., Dr. | Securing apparatus for fixing aspherical eyeball when performing lamellar keratotomies, includes suction channel having aspherical eyeball engaging surface comprising interior engaging surface and superior engaging surface |
US6818004B2 (en) | 2001-10-24 | 2004-11-16 | Cesar C. Carriazo | Aspherical positioning ring |
US20030114861A1 (en) | 2001-12-14 | 2003-06-19 | Carriazo Cesar C. | Adjustable suction ring |
RU2220522C2 (en) | 2002-01-08 | 2004-01-10 | Государственное научное учреждение Всероссийский научно-исследовательский и проектно-технологический институт механизации и электрификации сельского хозяйства | Method and apparatus for erosion-preventive plowing of slopes |
DE10214917A1 (en) | 2002-04-04 | 2003-10-16 | Gebauer Gmbh | Use for eye suction ring |
RU2200522C1 (en) | 2002-07-10 | 2003-03-20 | Джафарли Таир Баратович | Method for treating the cases of open angle glaucoma by applying pneumocyclodestruction |
EP2286773B1 (en) | 2002-07-19 | 2012-10-17 | Yale University | Uveoscleral drainage device |
US7645255B2 (en) * | 2004-03-22 | 2010-01-12 | Alcon, Inc. | Method of controlling a surgical system based on irrigation flow |
US7699780B2 (en) | 2004-08-11 | 2010-04-20 | Insightec—Image-Guided Treatment Ltd. | Focused ultrasound system with adaptive anatomical aperture shaping |
US20060064112A1 (en) * | 2004-09-08 | 2006-03-23 | Edward Perez | Ocular device applicator |
US8162858B2 (en) * | 2004-12-13 | 2012-04-24 | Us Hifu, Llc | Ultrasonic medical treatment device with variable focal zone |
CA2538465A1 (en) * | 2005-03-03 | 2006-09-03 | Riverside Research Institute | System and method for inducing controlled cardiac damage |
US20070016039A1 (en) | 2005-06-21 | 2007-01-18 | Insightec-Image Guided Treatment Ltd. | Controlled, non-linear focused ultrasound treatment |
EP1738725A1 (en) * | 2005-06-30 | 2007-01-03 | Wavelight Laser Technologie AG | Apparatus for eye surgery |
US8099162B2 (en) * | 2005-11-29 | 2012-01-17 | Eyegate Pharma, S.A.S. | Ocular iontophoresis device |
WO2007081750A2 (en) | 2006-01-06 | 2007-07-19 | The Curators Of The University Of Missouri | Ultrasound-mediated transcleral drug delivery |
WO2007084508A2 (en) * | 2006-01-13 | 2007-07-26 | Mirabilis Medica, Inc. | Apparatus for delivering high intensity focused ultrasound energy to a treatment site internal to a patient's body |
US20070203478A1 (en) * | 2006-02-21 | 2007-08-30 | Herekar Satish V | Method and system for elasto-modulation of ocular tissue |
AU2007286787B2 (en) | 2006-08-22 | 2012-09-20 | Donald N. Schwartz | Ultrasonic treatment of glaucoma |
FR2906165B1 (en) | 2006-09-27 | 2009-01-09 | Corneal Ind Soc Par Actions Si | ULTRASOUND EMISSION SYSTEM AND ULTRASONIC TREATMENT MACHINE INCORPORATING SAID SYSTEM |
JP5623749B2 (en) * | 2007-01-11 | 2014-11-12 | コーニンクレッカ フィリップス エヌ ヴェ | Catheter for 3D intracardiac echocardiography and system having same |
US8323296B2 (en) | 2007-03-15 | 2012-12-04 | Boris Malyugin | Ring used in a small pupil phacoemulsification procedure |
US8251908B2 (en) * | 2007-10-01 | 2012-08-28 | Insightec Ltd. | Motion compensated image-guided focused ultrasound therapy system |
EP2092916A1 (en) | 2008-02-19 | 2009-08-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof |
US8206326B2 (en) * | 2008-03-04 | 2012-06-26 | Sound Surgical Technologies, Llc | Combination ultrasound-phototherapy transducer |
IN2012DN02230A (en) | 2009-08-18 | 2015-08-21 | Eye Tech Care | |
FR2973685B1 (en) | 2011-04-05 | 2014-11-28 | Eye Tech Care | ULTRASOUND OCULAR THERAPY DEVICE WITH REFLECTOR |
-
2008
- 2008-02-19 EP EP08101765A patent/EP2092916A1/en not_active Ceased
-
2009
- 2009-02-18 RU RU2010138619/14A patent/RU2501539C2/en active
- 2009-02-18 CN CN200980105350.1A patent/CN101969899B/en active Active
- 2009-02-18 MX MX2010009027A patent/MX2010009027A/en active IP Right Grant
- 2009-02-18 CA CA2714116A patent/CA2714116C/en active Active
- 2009-02-18 JP JP2010547165A patent/JP2011512213A/en active Pending
- 2009-02-18 WO PCT/EP2009/051892 patent/WO2009103721A1/en active Application Filing
- 2009-02-18 ES ES09712991T patent/ES2426120T3/en active Active
- 2009-02-18 BR BRPI0908386A patent/BRPI0908386B8/en active IP Right Grant
- 2009-02-18 US US12/867,977 patent/US9403039B2/en active Active
- 2009-02-18 DK DK09712991.0T patent/DK2257251T3/en active
- 2009-02-18 EP EP09712991.0A patent/EP2257251B1/en active Active
- 2009-02-18 KR KR1020107020818A patent/KR101601798B1/en active IP Right Grant
- 2009-08-18 JP JP2011550430A patent/JP5490826B2/en active Active
- 2009-08-18 BR BRPI0924350A patent/BRPI0924350B8/en active IP Right Grant
- 2009-08-18 CN CN200980156978.4A patent/CN102316834B/en active Active
- 2009-08-26 US US13/202,084 patent/US9259597B2/en not_active Expired - Fee Related
-
2010
- 2010-08-05 IL IL207425A patent/IL207425A/en active IP Right Grant
-
2013
- 2013-09-19 JP JP2013194356A patent/JP5819372B2/en active Active
-
2016
- 2016-10-14 US US15/293,390 patent/US9931245B2/en active Active - Reinstated
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU591186A1 (en) * | 1976-07-23 | 1978-02-05 | Serov Vilenin Nikolaevich | Method of treating eye diseases |
US4484569A (en) * | 1981-03-13 | 1984-11-27 | Riverside Research Institute | Ultrasonic diagnostic and therapeutic transducer assembly and method for using |
DE4430720A1 (en) * | 1993-12-21 | 1995-06-22 | Zeiss Carl Fa | Laser cyclophotocoagulation device for treating glaucoma |
US20020016557A1 (en) * | 1997-02-14 | 2002-02-07 | Duarte Luiz R. | Ultrasonic treatment for wounds |
WO2001080708A2 (en) * | 2000-04-21 | 2001-11-01 | Txsonics Ltd. | Systems and methods for reducing secondary hot spots in a phased array focused ultrasound system |
US20080275370A1 (en) * | 2007-05-01 | 2008-11-06 | Mcintyre Jon T | Apparatus and method for treating visual disorders |
Non-Patent Citations (1)
Title |
---|
LIZZI & AL ED - BERKHOUT A J ET AL: "Ultrasonic therapy and imaging in ophtamology", STICAL IMAGING. THE HAGUE, 22 - 25 APRIL 1985; [PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON ACOUSTICAL IMAGING], NEW YORK, PLENUM PRESS, US, vol. 14, 1 January 1985 (1985-01-01), pages 1 - 17, XP002079832 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8652073B2 (en) | 2009-08-18 | 2014-02-18 | Eye Tech Care | Parameters for an ultrasound device comprising means to generate high intensity ultrasound beam |
EP2467108B1 (en) * | 2009-08-18 | 2020-01-08 | Eye Tech Care | Parameters for an ultrasound device comprising means to generate high intensity ultrasound beam |
FR2973685A1 (en) * | 2011-04-05 | 2012-10-12 | Eye Tech Care | ULTRASOUND OCULAR THERAPY DEVICE WITH REFLECTOR |
US8905949B2 (en) | 2011-04-05 | 2014-12-09 | Eye Tech Care | Device for ocular ultrasound therapy having a reflector |
WO2012136752A1 (en) | 2011-04-05 | 2012-10-11 | Eye Tech Care | Device for ocular ultrasound therapy having a reflector |
EP2601917A1 (en) | 2011-12-08 | 2013-06-12 | Eye Tech Care | System and method for determining the optimal size of a device for generating ultrasound |
US11097131B2 (en) | 2015-03-31 | 2021-08-24 | Eye Tech Care | Eye probe for treatment with ultrasonic waves |
WO2016177910A1 (en) | 2015-05-07 | 2016-11-10 | Eye Tech Care | Method for adjusting operating parameters for the power supply of a transducer |
US10695798B2 (en) | 2015-05-07 | 2020-06-30 | Eye Tech Care | Method for adjusting operating parameters for the power supply of a transducer |
WO2017053673A1 (en) * | 2015-09-24 | 2017-03-30 | Visionage Therapies, Llc | Sonic and ultrasonic methods and apparatus for treatment of glaucoma |
US11241334B2 (en) | 2015-09-24 | 2022-02-08 | Visionage Therapies, Llc | Sonic and ultrasonic contact lens apparatus |
FR3062057A1 (en) * | 2017-01-20 | 2018-07-27 | Eye Tech Care | OCULAR PROBE WITH MEANS FOR GENERATING ULTRASONIC DISPLACABLES |
FR3104409A1 (en) | 2019-12-16 | 2021-06-18 | Eye Tech Care | TREATMENT DEVICE INCLUDING A COUPLING FLUID DETECTOR |
WO2021122765A1 (en) | 2019-12-16 | 2021-06-24 | Eye Tech Care | Treatment device including a coupling liquid detector |
WO2021122762A1 (en) | 2019-12-16 | 2021-06-24 | Eye Tech Care | Treatment device including a tool-holder and a tool including contactless rotational movement means |
WO2021122764A1 (en) | 2019-12-16 | 2021-06-24 | Eye Tech Care | Processing device including a tool holder and a tool having rotational movement means with contact |
FR3104408A1 (en) | 2019-12-16 | 2021-06-18 | Eye Tech Care | PROCESSING DEVICE INCLUDING A TOOL HOLDER AND A TOOL INCLUDING MEANS OF MOVEMENT IN CONTACTLESS ROTATION |
FR3104410A1 (en) | 2019-12-16 | 2021-06-18 | Eye Tech Care | PROCESSING DEVICE INCLUDING A TOOL HOLDER AND A TOOL HAVING MEANS OF MOVEMENT IN CONTACT ROTATION |
CN115052567A (en) * | 2019-12-16 | 2022-09-13 | 护眼科技公司 | Treatment device comprising a tool holder and a tool with a non-contact rotary motion device |
US12133817B2 (en) | 2019-12-16 | 2024-11-05 | Eye Tech Care | Treatment device including a tool-holder and a tool including contactless rotational movement means |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9931245B2 (en) | High intensity focused ultrasound device with a concave segment shaped transducers for treatment of ocular pathology | |
CA2751906C (en) | Ultrasound device comprising means to generate ultrasound beam presenting a concave segment shape having a single curvature | |
US8652073B2 (en) | Parameters for an ultrasound device comprising means to generate high intensity ultrasound beam | |
US9517359B2 (en) | High intensity focused ultrasound device with a concave segment shaped transducer for eye treatment | |
WO2011083358A1 (en) | Device for treating an ocular pathology by applying doses of laser energy | |
AU2009216751B2 (en) | A method of treating an ocular pathology by applying high intensity focused ultrasound and device thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980105350.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09712991 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2714116 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 207425 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009216751 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12867977 Country of ref document: US Ref document number: MX/A/2010/009027 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010547165 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5180/CHENP/2010 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009712991 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009216751 Country of ref document: AU Date of ref document: 20090218 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20107020818 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010138619 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0908386 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100817 |